Abstract We examined compliance with and the effects of melatonin supplementation on breast cancer biomarkers (estradiol, insulin-like growth factor I (IGF-1), insulin-like growth factor-binding protein 3 (IGFBP-3), and the IGF-1/ IGFBP-3 ratio) in postmenopausal breast cancer survivors. In a double-blind, placebo-controlled study, postmenopausal women with a prior history of stages 0-III breast cancer who had completed active cancer treatment (including hormonal therapy) were randomly assigned to either 3 mg oral melatonin (n = 48) or placebo daily for 4 months. Plasma samples were collected at baseline and after the completion of the intervention. The primary endpoints were compliance and change in estradiol and IGF-1/IGFBP-3 levels. Ninety-five women were randomized (48 to melatonin and 47 to placebo). Eighty-six women (91%) completed the study and provided pre-and postintervention bloods. Melatonin was well tolerated without any grade 3/4 toxicity and compliance was high (89.5%). Overall, among postmenopausal women with a prior history of breast cancer, a 4-month course of 3 mg melatonin daily did not influence circulating estradiol, IGF-1, or IGFBP-3 levels. Compliance was comparable between the two groups. Short-term melatonin treatment did not influence the estradiol and IGF-1/IGBBP-3 levels. Effects of longer courses of melatonin among premenopausal women are unknown. Low baseline estradiol levels in our study population may have hindered the ability to detect any further estradiol-lowering effects of melatonin.
Introduction
Breast cancer is the most common cancer diagnosed in women in the United States, with modestly declining mortality rates over the past decade [1] . Both early detection and improvements in breast cancer therapy have been linked with this decline in mortality [2, 3] . However, comparatively little progress has been made in the prevention of breast cancer. Although tamoxifen and raloxifene have been approved by the FDA to reduce breast cancer risk, concern remains regarding its widespread use among healthy women because of tamoxifen's associations with endometrial cancer and with thromboembolic events [4] . No other drugs are currently known to effectively prevent breast cancer.
Epidemiologic and laboratory data suggest that melatonin may influence cancer risk, in particular breast cancer [5, 6] . The safety of melatonin supplementation in humans has been extensively documented with no significant adverse effects reported at a wide range of doses [7] . Because melatonin's effect on breast cancer risk is thought to work through several different mechanisms, it would make for a particularly attractive target drug for chemoprevention. The two primary mechanisms of melatonin in relation to breast cancer are its apparent influence on estrogens through down-regulation of the hypothalamicpituitary reproductive axis including a reduction in circulating estrogen levels [8] and through direct actions of melatonin at the tumor cell level, thus behaving both as a selective estrogen-receptor modulator and as an aromatase inhibitor [9, 10] . Secondly, melatonin blocks linoleic acid uptake and metabolism to 13-hydroxyoctadecadienoic acid (13-HODE), which, via down-regulation of the mitogenactivated protein/extracellular signal-regulated kinase (ERK) kinase (MEK) MEK/ERK1/2 growth signaling pathway, is directly related to the insulin-like growth factor (IGF) system [11] . Higher levels of circulating estradiol levels [12] , and to a lesser degree insulin-like growth factor [13] , are widely viewed as risk factors for postmenopausal breast cancer risk.
While several previous studies have suggested an association between melatonin and estradiol [14] [15] [16] [17] as well as IGF levels [15, [18] [19] [20] [21] [22] [23] [24] , none of these were randomized placebo-controlled trials. However, one small (n = 14) open-label study observed a significant decrease in circulating estradiol and IGF levels among postmenopausal women after 6 months of 2 mg melatonin daily [25] . To confirm this relationship, we conducted a double-blind, randomized, placebo-controlled trial of oral melatonin supplementation over 4 months in postmenopausal healthy survivors of early-stage breast cancer without current hormonal therapy use. We hypothesized that melatonin would lower estradiol and IGF levels and that compliance would be satisfactory. Because in the United States melatonin is sold as a dietary supplement and not as a drug and the endpoints were biomarkers, no trial registration number was assigned to this NIH-funded study.
Materials and methods

Eligibility criteria
To be eligible for enrollment, women had to have had a history of ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), or stages I-III breast cancer, not be currently receiving chemotherapy or hormonal therapy, be postmenopausal, understand written or spoken English, signed an informed consent, and have a normal liver and kidney function and complete blood count. Exclusion criteria were stage IV breast cancer or systemic recurrence; prior malignancies, other than breast, basal or squamous cell carcinoma of skin, or carcinoma in situ of the cervix; use of adjuvant hormonal therapy within 60 days; concomitant use of beta-blockers; concomitant, nightly use of sleep aids; working more than one overnight shift per month on a regular basis; concomitant use of postmenopausal hormone therapy, black cohosh, flaxseed, or soy in pill supplement; use of melatonin supplement within 30 days prior to enrollment; use of warfarin during the 30 days prior to enrollment; and active seizure disorder requiring daily antiepileptic medication. The study was approved by the Internal Review Board of the Dana-Farber Cancer Institute and Brigham and Women's Hospital, and written informed consent was obtained from each participant.
Randomization and masking
All women were recruited through the Breast Oncology Center at the Dana-Farber Cancer Institute (Boston, MA) and were randomly assigned by central pharmacy to receive in a double-blind fashion either 3 mg melatonin or placebo. Melatonin supplements were purchased from a single supplier (Rugby Laboratories, a subsidiary of Watson Laboratories, Duluth, GA, USA) by the DFCI Investigational Drug (ID) pharmacy. For each lot of melatonin, Rugby Laboratories issued a certificate of analysis guaranteeing the composition and purity. The DFCI ID pharmacy placed melatonin in blue gelatin capsules with methylcellulose filler and used identical blue capsules filled with methylcellulose filler alone as placebo. Distribution of medication and randomization were performed by the DFCI pharmacy. Subjects received a 4-month supply at the time of the baseline visit. Women who participated in the trial were instructed to take the assigned pill (melatonin or placebo) daily at 9 pm or 30 min before bedtime, whichever occurred earlier, for 4 months. Each subject was instructed to note any missed doses in her medication diary; missed doses were not replaced. The study team contacted each participant once monthly to follow-up on medication use, compliance, and side effects. All adverse events reporting in this trial used the National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3. Per protocol, the trial was to be suspended for any grade-3 or grade-4 adverse event that could possibly be related to the study intervention.
Outcome measurements
Prior to the beginning of the intervention and immediately after the completion of the 4-month intervention, subjects had their blood drawn to assess levels of circulating estradiol, IGF-1, and IGFBP-3. All blood samples were processed and stored at the DFCI. In addition, at both visits, assessments of sleep quality were made and medication use was assessed. Information on other covariates including height and weight was collected at each visit.
Blood samples Blood samples were drawn, then immediately processed and stored at -80F. A woman's initial and follow-up blood samples were assayed in the same batch, and we included masked quality control samples for analysis. Estradiol was measured in plasma by liquid chromatography tandem mass spectrometry (LC-MS/MS) at ARUP Laboratories (Salt Lake City, UT, USA). IGF-1 and IGFBP-3 levels were assayed by ELISA in Michael Pollak's laboratory (McGill University, Montreal, Canada), using reagents from Diagnostics Systems Laboratories (Webster, TX, USA). Laboratory data for IGF-1 and IGFBP-3 were reported with two replicated values at baseline and followup; these were averaged for each patient at each time point for the analysis. Data reported for estradiol did not include replicates. Twelve baseline and two follow-up estradiol measurements were reported as ''\1.0'', indicating that the level was below the lower limit of detection of the assay. For statistical analyses, the levels of these women were imputed at the lowest detectable level (1.0). None of the women who had ''\1.0'' reported at baseline also had ''\1.0'' reported at follow-up. The number of substitutions was identical between treatments (baseline: 6 melatonin, 6 placebo; 4-months: 1 melatonin, 1 placebo). We included masked split specimens to calculate the coefficient of variation. Mean intra-assay coefficients of variation were 18.9% for estradiol, 2.7% for IGF-1, and 2.7% for IGFBP-3.
Statistical analysis
Assuming an attrition rate of 15%, the accrual goal in this study was 50 participants per study arm with usable biomarker data. Due to the expiration of study funding, the trial was closed to accrual shortly before this goal was reached. Based on the 47 (placebo) and 48 (melatonin) women in each treatment arm at the end of the trial, we calculated that we had 80% power to detect a decrease from baseline in estradiol of 41% in the melatonin arm compared with 0% in the control arm. For comparison, with 50 participants per arm, we would have been able to detect a 38% decrease in estradiol. Because all hormones showed skewed distributions, log-transformed values were used for analyses. The primary trial analysis was performed according to the intent-to-treat principle. Wilcoxon ranksum tests were used to compare the ratios (or, equivalently, the difference in the natural log) of follow-up to baseline levels (i.e., 4 month/baseline) of estradiol, IGF-1, and IGFBP-3 between melatonin and placebo arms, and Fisher's exact test was calculated to compare compliance.
Results
Baseline demographics and tumor stage
Ninety-five postmenopausal women aged 38-80 were enrolled between March 2007 and March 2009. Fortyseven women were randomized to receive placebo and 48 to receive melatonin. Baseline characteristics were well balanced at the time of study entry. Table 1 summarizes baseline demographics and disease characteristics overall and by treatment assignment for all 95 women enrolled in the trial. Median age at enrollment was 59 years (placebo: 60 years, melatonin: 58 years), with an overall range of 38-80 years. Median age at breast cancer diagnosis was 50 years (range: 32-69), with a median time of 8 years after the diagnosis of breast cancer (range: 0.9-27.9 years). Median body mass index (BMI) at enrollment was 25.6 (range: 19.1-44.9) overall and 25.0 (range: 19.1-39.6) and 25.7 (range: 20.1-44.9) for those randomized to receive placebo and melatonin, respectively.
Attrition
Of 95 subjects enrolled, 86 (90.5%) completed the 4-month intervention and nine subjects (9.5%) did not complete the intervention. Of these, one subject withdrew consent for continued participation after approximately 7 weeks of follow-up due to insomnia (she was randomized to placebo). As part of the study eligibility criteria, she was required to stop her regular sleep medication and suffered severe insomnia as a result. Four subjects (all four in the melatonin arm) withdrew due to toxicity (all grades 1 or 2): one withdrew from the study after 11 weeks due to dizziness, fatigue, and headaches; the second subject withdrew after 13 weeks due to headaches, trouble sleeping, and bad dreams; the third and fourth subjects withdrew at 5 and 9 weeks, respectively, due to insomnia and nightmares. Three subjects were lost to follow-up (two on placebo and one on melatonin) and another subject left the study after 10 weeks to begin radiotherapy for local breast cancer recurrence (placebo).
Thus, 43 women enrolled and randomized to receive placebo (91.5%) completed the study, and 43 women enrolled and randomized to receive melatonin (86.9%) completed the study. The study was designed to allow for a 15% drop-out rate. The observed rate of attrition is 9.5% (8.5% placebo, 10.4% melatonin). There was no difference Cancer Causes Control (2012) 23: 609-616 611 in the rates of completion between the placebo and melatonin groups (Fisher's exact p-value = 0.75).
Circulating estradiol and IGF Eighty-six women had data assessable for changes in the primary biomarker endpoints (43 melatonin and 43 placebo). of the serum levels were below 6.3 for women in the placebo arm and below 8.1 for women in the melatonin arm. To explore whether overall relatively low baseline estradiol levels in our group of women could have prohibited a potential effect of melatonin on estradiol, in secondary analyses, we stratified by estradiol level (\3 pg/ml or C3 pg/ml); however, results remained essentially unchanged (data not shown). There was considerably more variability in the ratios of follow-up to baseline measures of estradiol compared with the ratios of IGF-1 and IGFBP-3 (Table 3 ). However, mean and median values were comparable between treatment groups for each of the markers. The 90th percentiles of the ratios for estradiol were 3.9 and 3.4 for placebo and melatonin, respectively. Wilcoxon ranksum p-values for the comparisons of the ratios between melatonin and placebo were 0.84 (estradiol), 0.36 (IGF-1), and 0.62 (IGFBP-3), suggesting that there is no difference between melatonin and placebo with respect to change in any of the three markers over the course of study follow-up.
Compliance
A subject was considered compliant if at least 75% of the pills were taken at the time of the final study visit (90 or more of 120 pills). Subjects who withdrew from the study before completion are considered non-compliant. Of the 95 subjects enrolled in the study, 10 were considered non-compliant (9 noncompleters and 1 who took less than 75% of the study medication). Therefore, compliance with the intervention occurred in 85 (42 in the placebo arm and 43 in the melatonin arm) of 95 subjects (89.5%). There was no difference in compliance between subjects who received placebo and subjects who received melatonin (Fisher's exact p-value = 0.99).
Toxicity and adverse events
Adverse events are summarized in Table 4 . For the melatonin arm, there were no grade 3/4 toxicities. The most common grade 1/2 toxicities for melatonin were headache, fatigue, and bad dreams.
Discussion
In this double-blind, randomized, placebo-controlled trial of oral melatonin supplementation over 4 months in 86 postmenopausal healthy survivors of early-stage breast cancer without current hormonal therapy use, we found no significant differences in circulating estradiol, IGF-1, and IGFBP-3 levels, as well as compliance, in relation to melatonin use. Compliance was high with daily melatonin and well tolerated. Melatonin appears to selectively neutralize both the effects of estrogens on the breast and the local biosynthesis of estrogens from androgens, thus acting at different levels of the estrogen-signaling pathway. It is difficult to foresee whether the net effect of these actions would lead to a reduction or an increase in circulating estrogen levels in our trial. Our primary hypothesis was that it will decrease estrogen, although we recognize that estrogen blockage may occur at the tissue level without influencing circulating levels (e.g., tamoxifen).
Several studies lend direct [14, 15] and indirect [16, 17] support to an inverse association between melatonin and estrogen levels. To date, one small study by Siegrist et al. did not find a significant association between 3 mg melatonin daily for 6 months and estrogen levels among 16 women, but this study did not take into account the differences in hormone levels during the menstrual cycle [26] . Two other more carefully conducted studies suggest that both low-dose (B5 mg daily) [15] and high-dose (300 mg daily) [14] melatonin supplementation may decrease estrogen levels in both post- [15] and premenopausal women [14] . Specifically, Pawlikowski et al. [15] administered 2 mg melatonin daily over 6 months in their small study of 14 women aged 64-80. They observed a significant decrease in estradiol levels after 6 months of melatonin in these postmenopausal women. Similarly, Voordouw et al. studied oral melatonin over 4 months, but chose to administer a much higher dose of 300 mg per day (8 received it daily and 4 on days 5-17 of their cycle) [14] . The daily melatonin administration caused a significant decrease in estrogen levels, but only after 4 months of treatment. No significant effect was seen after only 1 month of melatonin. In sum, several small pilot studies to date have provided some evidence for an effect of melatonin on estradiol levels, but ours is the first placebo-controlled, randomized study to evaluate these associations. Although less data exist on the relationship between melatonin and the IGF axis, several studies have also evaluated the effects of oral melatonin administration on circulating IGF-1 levels [15] or provided indirect evidence for an association between melatonin and the IGF axis [18] [19] [20] [21] [22] [23] . IGF remains an interesting outcome because of its possible association with a breast cancer risk pathway separate from a sex steroid hormonal mechanism. Although one study among postmenopausal women did not observe a strong association between IGF-1 levels and low-dose melatonin (2 mg daily), an inverse association between plasma melatonin and IGF-1 (r = -0.39, p = 0.06) was reported in a study of 24 premenopausal stage II breast cancer patients (compared to 16 healthy controls) [20] . Another trial among women with metastatic breast cancer also demonstrated a decrease in IGF-1 levels after melatonin supplementation. However, these women took melatonin and tamoxifen concurrently, so it was impossible to differentiate the effects of melatonin from those of tamoxifen [24] . Our results do not support an effect of oral melatonin, at the dose we used in our trial, on circulating IGF levels.
Melatonin has been used extensively in cancer patients, both alone and in combination with chemotherapy, with no significant adverse effects reported thus far, and they have been reviewed extensively elsewhere [27]; 20 mg daily was the most common dose of melatonin used in the clinical trials among the cancer patients. Two of these studies showed a statistically significant improvement in clinical response rate and overall survival among people with metastatic solid tumors randomly assigned to chemotherapy and melatonin compared to chemotherapy alone, as well as a decrease in chemotherapy-induced toxicity, such as neurotoxicity, thrombocytopenia, cachexia, and asthenia in the melatonin arm [28, 29] . The other two studies were single-arm studies in which tamoxifen 20 mg daily was given in combination with melatonin 20 mg daily [24, 30] . Again, the treatments were well tolerated without any significant adverse effects. We, too, did not observe any noteworthy adverse events in our placebocontrolled trial of 3 m melatonin daily.
Strengths of this study include its double-blind design, relatively large study population, and compliance rates comparable or better than observed in similar studies at the DFCI. That we fell slightly short of our accrual goal may have hampered our ability to detect the differences in the biomarkers we chose to evaluate; however, updated power analyses suggest that we still had a sufficient number of participants to detect an intervention effect close to our initial estimates. Our study may have been limited in detecting a potential lowering effect of melatonin on estradiol levels in that the majority of our postmenopausal participants were lean and with very low baseline estradiol to begin with (mean estradiol level at baseline = 3.97 pg/ml). Hence, we cannot rule out an effect of melatonin on estradiol levels in postmenopausal women with higher baseline estradiol levels (e.g., if their BMI, on average, is higher than in our study), or in premenopausal women.
In sum, this double-blind, randomized, placebo-controlled trial of oral melatonin supplementation did not support an important effect of 3 mg melatonin daily on circulating breast cancer biomarkers in postmenopausal women with a history of breast cancer, if given over 4 months. The effects of longer intake or different doses of melatonin, also in premenopausal women, need to be determined in future studies. Whether postmenopausal women with higher baseline estradiol levels than ours may have benefited from melatonin supplementation remains unclear.
Research into context
In this paper, we examined for the first time in a controlled fashion the effects of melatonin supplementation on breast cancer biomarkers. Melatonin was well tolerated without any grade 3/4 toxicity and compliance was high. Overall, among postmenopausal women with a prior history of breast cancer, a 4-month course of 3 mg melatonin daily did not influence circulating estradiol, IGF-1, or IGFBP-3 levels. We conclude that short-term melatonin treatment did not influence estradiol and IGF-1/IGBBP-3 levels. Effects of longer courses of melatonin among premenopausal women are unknown. Particularly, the low baseline estradiol levels in our postmenopausal, lean study population may have hindered our ability to detect any further estradiol-lowering effects of melatonin, and future studies should take this into consideration. 
